Jump Financial LLC Has $307,000 Holdings in OmniAb, Inc. (NASDAQ:OABI)

Jump Financial LLC lifted its stake in shares of OmniAb, Inc. (NASDAQ:OABI) by 157.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,732 shares of the company’s stock after buying an additional 30,386 shares during the quarter. Jump Financial LLC’s holdings in OmniAb were worth $307,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Federated Hermes Inc. acquired a new stake in OmniAb in the fourth quarter worth $38,000. Victory Capital Management Inc. grew its stake in shares of OmniAb by 22.9% in the 4th quarter. Victory Capital Management Inc. now owns 12,705 shares of the company’s stock valued at $78,000 after buying an additional 2,364 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in OmniAb in the 4th quarter valued at about $83,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in OmniAb by 56.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,772 shares of the company’s stock worth $116,000 after buying an additional 6,755 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in OmniAb during the 3rd quarter worth approximately $182,000. Institutional investors own 72.08% of the company’s stock.

OmniAb Trading Up 2.3 %

Shares of OmniAb stock opened at $4.39 on Friday. The company has a market capitalization of $516.31 million, a P/E ratio of -6.86 and a beta of -0.08. The stock has a fifty day simple moving average of $4.85 and a 200 day simple moving average of $5.28. OmniAb, Inc. has a 12-month low of $4.10 and a 12-month high of $6.72.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). OmniAb had a negative return on equity of 19.93% and a negative net margin of 301.62%. The firm had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same period in the prior year, the firm earned ($0.06) earnings per share. On average, analysts predict that OmniAb, Inc. will post -0.61 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Truist Financial restated a “buy” rating and set a $10.00 price objective on shares of OmniAb in a report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research note on Thursday, March 21st. Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research note on Tuesday, May 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $7.00 target price on shares of OmniAb in a research report on Thursday, March 21st.

Insiders Place Their Bets

In other OmniAb news, CFO Kurt A. Gustafson sold 6,954 shares of OmniAb stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $5.27, for a total transaction of $36,647.58. Following the transaction, the chief financial officer now owns 176,697 shares of the company’s stock, valued at approximately $931,193.19. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Kurt A. Gustafson sold 6,954 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $5.27, for a total value of $36,647.58. Following the completion of the transaction, the chief financial officer now directly owns 176,697 shares of the company’s stock, valued at $931,193.19. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kurt A. Gustafson sold 11,849 shares of OmniAb stock in a transaction on Monday, April 1st. The stock was sold at an average price of $5.46, for a total value of $64,695.54. Following the sale, the chief financial officer now owns 170,110 shares in the company, valued at $928,800.60. The disclosure for this sale can be found here. 8.60% of the stock is currently owned by insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.